JP2000512004A - 非誘導体化水溶性β(1―3)―グルカンのレセプター - Google Patents
非誘導体化水溶性β(1―3)―グルカンのレセプターInfo
- Publication number
- JP2000512004A JP2000512004A JP09539261A JP53926197A JP2000512004A JP 2000512004 A JP2000512004 A JP 2000512004A JP 09539261 A JP09539261 A JP 09539261A JP 53926197 A JP53926197 A JP 53926197A JP 2000512004 A JP2000512004 A JP 2000512004A
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- soluble
- water
- underivatized
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56961—Plant cells or fungi
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
- G01N2400/24—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar beta-D-Glucans, i.e. having beta 1,n (n=3,4,6) linkages between saccharide units, e.g. xanthan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
- G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記工程: a)炭水化物と糖脂質との相互作用に適する条件下で、糖脂質と炭水化物とを合 わせる工程; b)糖脂質に対する炭水化物のアフィニティーを決定する工程;および c)工程(b)で決定したアフィニティーを、炭水化物競合剤または糖脂質競合 剤の存在下でのアフィニティーと比較する工程、 それにより糖脂質に対する炭水化物のアフィニティーを評価する、 を含む、糖脂質に対する炭水化物のアフィニティーの評価アッセイ。 2. 糖脂質がLacCerである、請求項1記載のアッセイ。 3. 炭水化物が非誘導体化水溶性β(1−3)−グルカンである、請求項1記 載のアッセイ。 4. 下記工程: a)非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1−3) −グルカンレセプターへの結合に適する条件下で、放射性標識された非誘導 体化水溶性β(1−3)−グルカン、非誘導体化水溶性β(1−3)−グル カンレセプターおよび試験対象の作用剤を合わせる工程; b)非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1−3) −グルカンレセプターへの結合の程度を決定する工程;ならびに c)非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1−3) −グルカンレセプターへの結合に適する条件下で、工程(b)で決定した結 合の程度を、試験対象の作用剤の非存在下での結合の程度と比較する工程、 ここで、非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1− 3)−グルカンレセプターへの結合の程度の減少は、当該作用剤が非誘導体化水 溶性β(1−3)−グルカンレセプターに対するアフィニティーを有することを 示す、 を含む、非誘導体化水溶性β(1−3)−グルカンレセプターに対するアフィニ ティーを有する作用剤の同定アッセイ。 5. レセプターがラクトシルセラミドである、請求項4記載のアッセイ。 6. レセプターが非誘導体化水溶性β(1−3)−グルカンに対するアフィニ ティーを有する化合物である、請求項4記載のアッセイ。 7. 化合物がレセプターアナログまたはレセプター模倣物である、請求項6記 載のアッセイ。 8. 下記工程: a)炭水化物と糖脂質との相互作用に適する条件下で、放射性標識された炭水化 物、糖脂質および試験対象の作用剤を合わせる工程; b)炭水化物の糖脂質への結合の程度を決定する工程;ならびに c)炭水化物と糖脂質との相互作用に適する条件下で、工程(b)で決定した結 合の程度を試験対象の作用剤の非存在下での結合の程度と比較する工程、 ここで、炭水化物の糖脂質への結合の程度の差は、当該作用剤が炭水化物の糖脂 質への結合を変化させることを示す、 を含む、炭水化物の糖脂質への結合を変化させる作用剤の同定アッセイ。 9. 炭水化物が非誘導体化水溶性β(1−3)−グルカンである、請求項8記 載のアッセイ。 10. 糖脂質が非誘導体化水溶性β(1−3)−グルカンレセプターである、 請求項8記載のアッセイ。 11. 糖脂質がラクトシルセラミドである、請求項10記載のアッセイ。 12. 作用剤が非誘導体化水溶性β(1−3)−グルカンレセプターのアゴニ ストである、請求項8記載のアッセイ。 13. 作用剤が非誘導体化水溶性β(1−3)−グルカンレセプターのアンタ ゴニストである、請求項8記載のアッセイ。 14. 請求項8記載のアッセイにより同定される作用剤。 15. レセプターが非誘導体化水溶性β(1−3)−グルカンに対するアフィ ニティーを有する化合物である、請求項10記載のアッセイ。 16. 化合物がレセプターアナログまたはレセプター模倣物である、請求項1 5記載のアッセイ。 17. 下記工程: a)送達対象の作用剤を非誘導体化水溶性β(1−3)−グルカンにコンジュゲ ート化させて、コンジュゲート分子を製造する工程;および b)コンジュゲート分子の非誘導体化水溶性β(1−3)−グルカンが非誘導体 化水溶性β(1−3)−グルカンレセプターに結合するのに適した条件下で 、当該コンジュゲート分子を投与する工程、 それによって、非誘導体化水溶性β(1−3)−グルカンレセプターを含有する 細胞において、非誘導体化水溶性β(1−3)−グルカンが非誘導体化水溶性β (1−3)−グルカンレセプターに結合し、そうすることにより、コンジュゲー ト分子の作用剤を当該細胞に送達する、 を含む、非誘導体化水溶性β(1−3)−グルカンレセプターを含有する細胞へ の作用剤の送達方法。 18. レセプターがラクトシルセラミドである、請求項17記載の方法。 19. レセプターが非誘導体化水溶性β(1−3)−グルカンに対するアフィ ニティーを有する化合物である、請求項17記載の方法。 20. 化合物がレセプターアナログまたはレセプター模倣物である、請求項1 9記載の方法。 21. 下記工程: a)非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1−3) −グルカンレセプターへの結合に適する条件下で、非誘導体化水溶性β(1 −3)−グルカン、非誘導体化水溶性β(1−3)−グルカンレセプターお よび試験対象の作用剤を合わせる工程; b)シグナル伝達経路の活性化の程度を決定する工程;ならびに c)非誘導体化水溶性β(1−3)−グルカンの非誘導体化水溶性β(1−3) −グルカンレセプターへの結合に適する条件下で、工程(b)で決定した活 性化の程度を、試験対象の作用剤の非存在下での活性化の程度と比較する工 程、 ここで、シグナル伝達経路の活性化の程度の差は、当該作用剤がシグナル伝達経 路の活性化における非誘導体化水溶性β(1−3)−グルカンの効果を変化させ ることを示す、 を含む、シグナル伝達経路の活性化における非誘導体化水溶性β(1−3)−グ ルカンの効果を変化させる作用剤の同定アッセイ。 22. 活性化の程度が作用剤の非存在下よりも作用剤の存在下の方が大きい場 合、作用剤は、シグナル伝達経路の活性化における非誘導体化水溶性β(1−3 )−グルカンの効果を高めるものである、請求項21記載のアッセイ。 23. 活性化の程度が作用剤の非存在下よりも作用剤の存在下の方が小さい場 合、作用剤は、シグナル伝達経路の活性化における非誘導体化水溶性β(1−3 )−グルカンの効果を減少させるものである、請求項21記載のアッセイ。 24. シグナル伝達経路の活性化が少なくとも1つの転写調節因子の調節によ り測定される、請求項21記載のアッセイ。 25. 転写調節因子がNF−κB、NF−IL6またはjun/fosファミ リーのメンバーからなる群より選ばれるものである、請求項24記載のアッセイ 。 26. 工程(b)が転写調節因子に特異的な32P標識DNAオリゴヌクレオチ ドにより行なわれる、請求項21記載のアッセイ。 27. 請求項21記載のアッセイにより同定される作用剤。 28. a)非誘導体化水溶性β(1−3)−グルカンレセプターを含有する細 胞を、非誘導体化水溶性β(1−3)−グルカンレセプターに結合して活性化さ せる作用剤と接触させる工程、 それによって、非誘導体化水溶性β(1−3)−グルカンレセプターが活性化さ れ、そうすることにより、シグナル伝達経路を活性化させる、 を含む、非誘導体化水溶性β(1−3)−グルカンレセプターを含有する細胞に おけるシグナル伝達経路を活性化させる方法。 29. シグナル伝達経路の活性化が少なくとも1つの転写調節因子の調節によ り測定される、請求項28記載の方法。 30. 転写調節因子がNF−κB、NF−IL6またはjun/fosファミ リーのメンバーからなる群より選ばれるものである、請求項29記載の方法。 31. 作用剤が非誘導体化水溶性β(1−3)−グルカンである、請求項28 記載の方法。 32. レセプターがラクトシルセラミドである、請求項21記載のアッセイ。 33. レセプターが非誘導体化水溶性β(1−3)−グルカンに対するアフィ ニティーを有する化合物である、請求項21記載のアッセイ。 34. 化合物がレセプターアナログまたはレセプター模倣物である、請求項3 3記載のアッセイ。 35. レセプターがラクトシルセラミドである、請求項28記載の方法。 36. レセプターが非誘導体化水溶性β(1−3)−グルカンに対するアフィ ニティーを有する化合物である、請求項28記載の方法。 37. 化合物がレセプターアナログまたはレセプター模倣物である、請求項3 6記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63793496A | 1996-05-01 | 1996-05-01 | |
US08/664,173 US6090938A (en) | 1996-05-01 | 1996-06-14 | Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan |
US08/637,934 | 1997-01-31 | ||
US08/797,696 US6110692A (en) | 1996-05-01 | 1997-01-31 | Receptor for underivatized aqueous soluble β(1-3)-glucan |
US08/664,173 | 1997-01-31 | ||
US08/797,696 | 1997-01-31 | ||
PCT/US1997/007445 WO1997041439A1 (en) | 1996-05-01 | 1997-05-01 | RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE β(1-3)-GLUCAN |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000512004A true JP2000512004A (ja) | 2000-09-12 |
JP3920349B2 JP3920349B2 (ja) | 2007-05-30 |
Family
ID=27417615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53926197A Expired - Fee Related JP3920349B2 (ja) | 1996-05-01 | 1997-05-01 | 非誘導体化水溶性β(1―3)―グルカンのレセプター |
Country Status (10)
Country | Link |
---|---|
US (2) | US6110692A (ja) |
EP (1) | EP0900379B1 (ja) |
JP (1) | JP3920349B2 (ja) |
KR (1) | KR100561660B1 (ja) |
AT (1) | ATE265046T1 (ja) |
AU (1) | AU718650B2 (ja) |
CA (1) | CA2253257C (ja) |
DE (1) | DE69728760T2 (ja) |
ES (1) | ES2223079T3 (ja) |
WO (1) | WO1997041439A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011102323A (ja) * | 1998-08-26 | 2011-05-26 | Biothera Inc | 非誘導化水溶性ベータ−(1,3)−グルカンのレセプター |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110692A (en) | 1996-05-01 | 2000-08-29 | The Collaborative Group, Ltd. | Receptor for underivatized aqueous soluble β(1-3)-glucan |
US6084092A (en) * | 1997-01-31 | 2000-07-04 | The Collaborative Group, Ltd. | β(1-3)-glucan diagnostic assays |
US6413715B2 (en) * | 1997-01-31 | 2002-07-02 | The Collaborative Group | β(1-3)-glucan diagnostic assays |
WO1999031504A1 (en) * | 1997-12-12 | 1999-06-24 | Alpha-Beta Technology, Inc. | ACTIVATION OF TRANSCRIPTION FACTOR COMPLEX BY β(1-3) GLUCAN |
NO20014256D0 (no) * | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Fremstilling av immunstimulerende forbindelse |
US7514085B2 (en) | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
EP1877447B1 (en) | 2005-05-05 | 2016-12-21 | Sensient Flavors Inc. | Production of beta-glucans and mannans |
WO2006133707A2 (en) | 2005-06-15 | 2006-12-21 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
US20090005340A1 (en) * | 2005-06-15 | 2009-01-01 | Medimush A/S | Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell |
CN101553261B (zh) * | 2006-06-15 | 2014-01-29 | 生物高聚物工程公司Dba生物治疗公司 | 葡聚糖的制备 |
WO2008027580A2 (en) * | 2006-09-01 | 2008-03-06 | University Of Louisville | PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS |
WO2008027581A1 (en) * | 2006-09-01 | 2008-03-06 | University Of Louisville | Mcrp antagonists and their uses |
CA2766288C (en) | 2009-06-26 | 2020-05-05 | Charles River Laboratories, Inc. | Heat-treated limulus amebocyte lysates |
US20110293784A1 (en) | 2010-05-28 | 2011-12-01 | Anja Wittke | Milk-based nutritional compositions |
US20130028882A1 (en) | 2011-07-07 | 2013-01-31 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
ES2877099T3 (es) | 2014-07-10 | 2021-11-16 | Hibercell Inc | Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral |
JP6887378B2 (ja) | 2014-11-06 | 2021-06-16 | バイオセラ,インク. | 腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物 |
WO2018156888A1 (en) | 2017-02-24 | 2018-08-30 | Biothera Pharmaceuticals, Inc. | Beta glucan immunopharmacodynamics |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8304006D0 (sv) * | 1983-07-15 | 1983-07-15 | Karlsson Karl Anders | Forening och komposition for terapeutisk eller diagnostisk anvendning samt forfarande for terapeutisk behandling |
US5217715A (en) * | 1988-08-01 | 1993-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Carbohydrate receptor for bacteria and method for use thereof |
US5089479A (en) * | 1988-11-28 | 1992-02-18 | Krivan Howard C | Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide |
US5225330A (en) * | 1988-08-01 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic kit and diagnostic method utilizing carbohydrate receptors |
JPH02250834A (ja) * | 1989-03-24 | 1990-10-08 | Snow Brand Milk Prod Co Ltd | 脱髄疾患治療剤 |
US5032401A (en) * | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5488040A (en) | 1989-09-08 | 1996-01-30 | Alpha-Beta Technology, Inc. | Use of neutral soluble glucan preparations to stimulate platelet production |
US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
AU650626B2 (en) * | 1989-09-08 | 1994-06-30 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
US5242800A (en) * | 1990-01-30 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Receptor for pathogenic fungi |
JP2944709B2 (ja) | 1990-06-21 | 1999-09-06 | 生化学工業株式会社 | (1→3)―β―D―グルカンの測定剤 |
US5156948A (en) | 1990-07-20 | 1992-10-20 | Christensen Dale A | Method and kit for diagnosis of diseases |
AU658408B2 (en) | 1991-03-14 | 1995-04-13 | Seikagaku Corporation | (1-3)-beta -D-glucan assaying agent |
JPH04346791A (ja) | 1991-05-21 | 1992-12-02 | Taito Kk | 単クローン抗体 |
DE69211973T2 (de) | 1991-12-25 | 1996-12-19 | Maruha Corp | Reagenzien und Verfahren zur Bestimmung von Beta-Glucanen |
JP3524120B2 (ja) | 1992-05-08 | 2004-05-10 | 生化学工業株式会社 | 前処理剤、前処理方法、前処理された試料による測定法、測定用キット及び試料の判定方法 |
JP3322700B2 (ja) | 1992-09-14 | 2002-09-09 | 生化学工業株式会社 | 固相系反応用エンドトキシン特異的測定剤 |
JPH0853488A (ja) * | 1994-08-12 | 1996-02-27 | Daikin Ind Ltd | 6’−フルオロラクトシルセラミド、その中間体およびその製造方法 |
CN1120847C (zh) | 1994-09-01 | 2003-09-10 | 生化学工业株式会社 | (1→3)-β-D-葡聚糖结合性蛋白质、识别该蛋白质的抗体及其利用 |
US6110692A (en) | 1996-05-01 | 2000-08-29 | The Collaborative Group, Ltd. | Receptor for underivatized aqueous soluble β(1-3)-glucan |
-
1997
- 1997-01-31 US US08/797,696 patent/US6110692A/en not_active Expired - Lifetime
- 1997-05-01 WO PCT/US1997/007445 patent/WO1997041439A1/en not_active Application Discontinuation
- 1997-05-01 KR KR1019980708877A patent/KR100561660B1/ko not_active IP Right Cessation
- 1997-05-01 DE DE69728760T patent/DE69728760T2/de not_active Expired - Lifetime
- 1997-05-01 JP JP53926197A patent/JP3920349B2/ja not_active Expired - Fee Related
- 1997-05-01 ES ES97926398T patent/ES2223079T3/es not_active Expired - Lifetime
- 1997-05-01 AU AU31171/97A patent/AU718650B2/en not_active Expired
- 1997-05-01 CA CA002253257A patent/CA2253257C/en not_active Expired - Lifetime
- 1997-05-01 AT AT97926398T patent/ATE265046T1/de active
- 1997-05-01 EP EP97926398A patent/EP0900379B1/en not_active Expired - Lifetime
-
1998
- 1998-10-30 US US09/183,676 patent/US6630310B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011102323A (ja) * | 1998-08-26 | 2011-05-26 | Biothera Inc | 非誘導化水溶性ベータ−(1,3)−グルカンのレセプター |
Also Published As
Publication number | Publication date |
---|---|
DE69728760T2 (de) | 2005-03-31 |
WO1997041439A1 (en) | 1997-11-06 |
EP0900379A1 (en) | 1999-03-10 |
CA2253257C (en) | 2007-11-13 |
US6630310B1 (en) | 2003-10-07 |
JP3920349B2 (ja) | 2007-05-30 |
KR20000065194A (ko) | 2000-11-06 |
AU3117197A (en) | 1997-11-19 |
US6110692A (en) | 2000-08-29 |
EP0900379B1 (en) | 2004-04-21 |
KR100561660B1 (ko) | 2006-11-30 |
CA2253257A1 (en) | 1997-11-06 |
ATE265046T1 (de) | 2004-05-15 |
DE69728760D1 (de) | 2004-05-27 |
AU718650B2 (en) | 2000-04-20 |
ES2223079T3 (es) | 2005-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000512004A (ja) | 非誘導体化水溶性β(1―3)―グルカンのレセプター | |
Wright et al. | Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide. | |
Hillery et al. | Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin | |
Raetz et al. | Gram‐negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction 1 | |
US5318890A (en) | Assays for inhibitors of leukocyte adhesion | |
Iwabuchi et al. | Involvement of very long fatty acid-containing lactosylceramide in lactosylceramide-mediated superoxide generation and migration in neutrophils | |
Galili et al. | Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction. | |
US5928624A (en) | Compositions for neutralization of lipopolysaccharides | |
US6362010B1 (en) | Methods and compositions for release of CD3430 cells from affinity matrices | |
US6090938A (en) | Activation of signal transduction by underivatized, aqueous soluble . .beta(1-3)-Glucan | |
Morrison | The case for specific lipopolysaccharide receptors expressed on mammalian cells | |
Katz et al. | Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin | |
Nogare et al. | A comparison of the effects of intact and deacylated lipopolysaccharide on human polymorphonuclear leukocytes. | |
Cain et al. | Solubilization of glycosyl-phosphatidylinositol-anchored proteins in quiescent and stimulated neutrophils | |
Joseph et al. | Platelet activation markers and the primary antiphospholipid syndrome (PAPS) | |
El‐Samalouti et al. | Detection of Lipopolysaccharide (LPS)‐Binding Membrane Proteins by Immuno‐Coprecipitation with LPS and Anti‐LPS Antibodies | |
Jacobs | Structural features of binding of lipopolysaccharides to murine lymphocytes | |
Haugen et al. | CD14 expression and binding of lipopolysaccharide to alveolar macrophages and monocytes | |
Uragoh et al. | A novel immunohistochemical method for in vivo detection of endotoxin using horseshoe crab factor C. | |
Kolb-Bachofen | A membrane-bound form of the acute-phase protein C-reactive protein is the galactose-specific particle receptor on rat liver macrophages | |
Rodeberg et al. | Role of calcium during lipopolysaccharide stimulation of neutrophils | |
Karlsson et al. | Different glycosphingolipid composition in human neutrophil subcellular compartments | |
Mukherjee et al. | Organization and mobility of CD11b/CD18 and targeting of superoxide on the surface of degranulated human neutrophils | |
Weersink et al. | Modulation of lipopolysaccharide binding to human granulocytes. | |
Iwabuchi | Structure and functions of glycosignaling domain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060413 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070215 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110223 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120223 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130223 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140223 Year of fee payment: 7 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |